David Parkes, PhD
Chief Scientific Officer
Dr. David Parkes has ~25 years’ experience in scientific discovery and drug development in diabetes, obesity, NAFLD/NASH and cardiovascular disease. He held senior level roles in Discovery Research and Medical Affairs at Amylin, following extensive training in globally-recognized medical research institutes including the Salk Institute. He played pivotal roles in development of exenatide, pramlintide and metreleptin, three first in class drugs for treatment of metabolic diseases. He is currently a scientific consultant for companies including Astra Zeneca, Gilead, Prosciento and Prolynx. David received his PhD in Pharmacology from the University of Melbourne, and has published ~100 articles in high-impact journals.